Bee venom phospholipase A2 suppresses allergic airway inflammation in an ovalbumin‐induced asthma model through the induction of regulatory T cells

Bee venom (BV) is one of the alternative medicines that have been widely used in the treatment of chronic inflammatory diseases. We previously demonstrated that BV induces immune tolerance by increasing the population of regulatory T cells (Tregs) in immune disorders. However, the major component an...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Immunity, Inflammation and Disease Inflammation and Disease, 2015-12, Vol.3 (4), p.386-397
Hauptverfasser: Park, Soojin, Baek, Hyunjung, Jung, Kyung‐Hwa, Lee, Gihyun, Lee, Hyeonhoon, Kang, Geun‐Hyung, Lee, Gyeseok, Bae, Hyunsu
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 397
container_issue 4
container_start_page 386
container_title Immunity, Inflammation and Disease
container_volume 3
creator Park, Soojin
Baek, Hyunjung
Jung, Kyung‐Hwa
Lee, Gihyun
Lee, Hyeonhoon
Kang, Geun‐Hyung
Lee, Gyeseok
Bae, Hyunsu
description Bee venom (BV) is one of the alternative medicines that have been widely used in the treatment of chronic inflammatory diseases. We previously demonstrated that BV induces immune tolerance by increasing the population of regulatory T cells (Tregs) in immune disorders. However, the major component and how it regulates the immune response have not been elucidated. We investigated whether bee venom phospholipase A2 (bvPLA2) exerts protective effects that are mediated via Tregs in OVA‐induced asthma model. bvPLA2 was administered by intraperitoneal injection into control and OVA‐challenged mice. The Treg population, total and differential bronchoalveolar lavage fluid (BALF) cell count, Th2 cytokines, and lung histological features were assessed. Treg depletion was used to determine the involvement of Treg migration and the reduction of asthmatic symptoms. The CD206‐dependence of bvPLA2‐treated suppression of airway inflammation was evaluated in OVA‐challenged CD206‐/‐ mice. The bvPLA2 treatment induced the Tregs and reduced the infiltration of inflammatory cells into the lung in the OVA‐challenged mice. Th2 cytokines in the bronchoalveolar lavage fluid (BALF) were reduced in bvPLA2‐treated mice. Although bvPLA2 suppressed the number of inflammatory cells after OVA challenge, these effects were not observed in Treg‐depleted mice. In addition, we investigated the involvement of CD206 in bvPLA2‐mediated immune tolerance in OVA‐induced asthma model. We observed a significant reduction in the levels of Th2 cytokines and inflammatory cells in the BALF of bvPLA2‐treated OVA‐induced mice but not in bvPLA2‐treated OVA‐induced CD206‐/‐ mice. These results demonstrated that bvPLA2 can mitigate airway inflammation by the induction of Tregs in an OVA‐induced asthma model. bvPLA2, as a modulator of Treg population, suppresses allergic inflammation in OVA‐induced asthma model. bvPLA2‐induced Treg recruitment to the lungs is correlated with CD206 to ameliorate allergic inflammation.
doi_str_mv 10.1002/iid3.76
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4693726</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1754524861</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4616-1c8ebf3122156fb68236a3bdc0ed0cb23ac1a6fd247a112b5381057ee20c96513</originalsourceid><addsrcrecordid>eNp1kctq3DAUhk1paUIa-gZF0EULYVJdbMmzKeTSy0Cgm3QtjuXjGQVZciV7wuz6CN30BfsklTNpSAtdiKODPv3nP_xF8ZLRU0Ypf2dtK06VfFIcclrRRVlx9fTR_aA4TumGUsqoUILWz4sDLpUoS0kPi5_niGSLPvRk2ISUj7MDJCRnnKRpGCKmhImAcxjX1hCw8RZ2xPrOQd_DaIPPDQFPwhZcM_XW__r-w_p2MtgSSOOmB9KHFh0ZNzFM602uSO6Au8-hIxHXk4MxxB25JgadSy-KZx24hMf39aj4-vHD9cXnxdWXT6uLs6uFKSWTC2ZqbDrBOGeV7BpZcyFBNK2h2FLTcAGGgexaXipgjDeVqBmtFCKnZikrJo6K93vdYWp6bA36MYLTQ7Q9xJ0OYPXfL95u9DpsdSmXQnGZBd7eC8TwbcI06t6meQXwGKakmapyBGUt51mv_0FvwhR9Xk9zXi8VE9lSpt7sKRNDShG7BzOM6jltPaet1Tz61WPvD9yfbDNwsgdurcPd_3T0anUpstxv26228g</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2289713965</pqid></control><display><type>article</type><title>Bee venom phospholipase A2 suppresses allergic airway inflammation in an ovalbumin‐induced asthma model through the induction of regulatory T cells</title><source>DOAJ Directory of Open Access Journals</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Wiley-Blackwell Open Access Titles</source><source>PubMed Central</source><creator>Park, Soojin ; Baek, Hyunjung ; Jung, Kyung‐Hwa ; Lee, Gihyun ; Lee, Hyeonhoon ; Kang, Geun‐Hyung ; Lee, Gyeseok ; Bae, Hyunsu</creator><creatorcontrib>Park, Soojin ; Baek, Hyunjung ; Jung, Kyung‐Hwa ; Lee, Gihyun ; Lee, Hyeonhoon ; Kang, Geun‐Hyung ; Lee, Gyeseok ; Bae, Hyunsu</creatorcontrib><description>Bee venom (BV) is one of the alternative medicines that have been widely used in the treatment of chronic inflammatory diseases. We previously demonstrated that BV induces immune tolerance by increasing the population of regulatory T cells (Tregs) in immune disorders. However, the major component and how it regulates the immune response have not been elucidated. We investigated whether bee venom phospholipase A2 (bvPLA2) exerts protective effects that are mediated via Tregs in OVA‐induced asthma model. bvPLA2 was administered by intraperitoneal injection into control and OVA‐challenged mice. The Treg population, total and differential bronchoalveolar lavage fluid (BALF) cell count, Th2 cytokines, and lung histological features were assessed. Treg depletion was used to determine the involvement of Treg migration and the reduction of asthmatic symptoms. The CD206‐dependence of bvPLA2‐treated suppression of airway inflammation was evaluated in OVA‐challenged CD206‐/‐ mice. The bvPLA2 treatment induced the Tregs and reduced the infiltration of inflammatory cells into the lung in the OVA‐challenged mice. Th2 cytokines in the bronchoalveolar lavage fluid (BALF) were reduced in bvPLA2‐treated mice. Although bvPLA2 suppressed the number of inflammatory cells after OVA challenge, these effects were not observed in Treg‐depleted mice. In addition, we investigated the involvement of CD206 in bvPLA2‐mediated immune tolerance in OVA‐induced asthma model. We observed a significant reduction in the levels of Th2 cytokines and inflammatory cells in the BALF of bvPLA2‐treated OVA‐induced mice but not in bvPLA2‐treated OVA‐induced CD206‐/‐ mice. These results demonstrated that bvPLA2 can mitigate airway inflammation by the induction of Tregs in an OVA‐induced asthma model. bvPLA2, as a modulator of Treg population, suppresses allergic inflammation in OVA‐induced asthma model. bvPLA2‐induced Treg recruitment to the lungs is correlated with CD206 to ameliorate allergic inflammation.</description><identifier>ISSN: 2050-4527</identifier><identifier>EISSN: 2050-4527</identifier><identifier>DOI: 10.1002/iid3.76</identifier><identifier>PMID: 26734460</identifier><language>eng</language><publisher>England: John Wiley &amp; Sons, Inc</publisher><subject>Allergies ; Arthritis ; Asthma ; Binding sites ; bvPLA2 ; Cytokines ; Gene expression ; Immunoglobulins ; Inflammation ; Lymphocytes ; mannose receptor (CD206) ; Original Research ; regulatory T cells ; Signal transduction ; Tuberculosis ; Venom</subject><ispartof>Immunity, Inflammation and Disease, 2015-12, Vol.3 (4), p.386-397</ispartof><rights>2015 The Authors. Published by John Wiley &amp; Sons Ltd.</rights><rights>2015. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4616-1c8ebf3122156fb68236a3bdc0ed0cb23ac1a6fd247a112b5381057ee20c96513</citedby><cites>FETCH-LOGICAL-c4616-1c8ebf3122156fb68236a3bdc0ed0cb23ac1a6fd247a112b5381057ee20c96513</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693726/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693726/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,725,778,782,862,883,1414,11549,27911,27912,45561,45562,46039,46463,53778,53780</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26734460$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Park, Soojin</creatorcontrib><creatorcontrib>Baek, Hyunjung</creatorcontrib><creatorcontrib>Jung, Kyung‐Hwa</creatorcontrib><creatorcontrib>Lee, Gihyun</creatorcontrib><creatorcontrib>Lee, Hyeonhoon</creatorcontrib><creatorcontrib>Kang, Geun‐Hyung</creatorcontrib><creatorcontrib>Lee, Gyeseok</creatorcontrib><creatorcontrib>Bae, Hyunsu</creatorcontrib><title>Bee venom phospholipase A2 suppresses allergic airway inflammation in an ovalbumin‐induced asthma model through the induction of regulatory T cells</title><title>Immunity, Inflammation and Disease</title><addtitle>Immun Inflamm Dis</addtitle><description>Bee venom (BV) is one of the alternative medicines that have been widely used in the treatment of chronic inflammatory diseases. We previously demonstrated that BV induces immune tolerance by increasing the population of regulatory T cells (Tregs) in immune disorders. However, the major component and how it regulates the immune response have not been elucidated. We investigated whether bee venom phospholipase A2 (bvPLA2) exerts protective effects that are mediated via Tregs in OVA‐induced asthma model. bvPLA2 was administered by intraperitoneal injection into control and OVA‐challenged mice. The Treg population, total and differential bronchoalveolar lavage fluid (BALF) cell count, Th2 cytokines, and lung histological features were assessed. Treg depletion was used to determine the involvement of Treg migration and the reduction of asthmatic symptoms. The CD206‐dependence of bvPLA2‐treated suppression of airway inflammation was evaluated in OVA‐challenged CD206‐/‐ mice. The bvPLA2 treatment induced the Tregs and reduced the infiltration of inflammatory cells into the lung in the OVA‐challenged mice. Th2 cytokines in the bronchoalveolar lavage fluid (BALF) were reduced in bvPLA2‐treated mice. Although bvPLA2 suppressed the number of inflammatory cells after OVA challenge, these effects were not observed in Treg‐depleted mice. In addition, we investigated the involvement of CD206 in bvPLA2‐mediated immune tolerance in OVA‐induced asthma model. We observed a significant reduction in the levels of Th2 cytokines and inflammatory cells in the BALF of bvPLA2‐treated OVA‐induced mice but not in bvPLA2‐treated OVA‐induced CD206‐/‐ mice. These results demonstrated that bvPLA2 can mitigate airway inflammation by the induction of Tregs in an OVA‐induced asthma model. bvPLA2, as a modulator of Treg population, suppresses allergic inflammation in OVA‐induced asthma model. bvPLA2‐induced Treg recruitment to the lungs is correlated with CD206 to ameliorate allergic inflammation.</description><subject>Allergies</subject><subject>Arthritis</subject><subject>Asthma</subject><subject>Binding sites</subject><subject>bvPLA2</subject><subject>Cytokines</subject><subject>Gene expression</subject><subject>Immunoglobulins</subject><subject>Inflammation</subject><subject>Lymphocytes</subject><subject>mannose receptor (CD206)</subject><subject>Original Research</subject><subject>regulatory T cells</subject><subject>Signal transduction</subject><subject>Tuberculosis</subject><subject>Venom</subject><issn>2050-4527</issn><issn>2050-4527</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>WIN</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNp1kctq3DAUhk1paUIa-gZF0EULYVJdbMmzKeTSy0Cgm3QtjuXjGQVZciV7wuz6CN30BfsklTNpSAtdiKODPv3nP_xF8ZLRU0Ypf2dtK06VfFIcclrRRVlx9fTR_aA4TumGUsqoUILWz4sDLpUoS0kPi5_niGSLPvRk2ISUj7MDJCRnnKRpGCKmhImAcxjX1hCw8RZ2xPrOQd_DaIPPDQFPwhZcM_XW__r-w_p2MtgSSOOmB9KHFh0ZNzFM602uSO6Au8-hIxHXk4MxxB25JgadSy-KZx24hMf39aj4-vHD9cXnxdWXT6uLs6uFKSWTC2ZqbDrBOGeV7BpZcyFBNK2h2FLTcAGGgexaXipgjDeVqBmtFCKnZikrJo6K93vdYWp6bA36MYLTQ7Q9xJ0OYPXfL95u9DpsdSmXQnGZBd7eC8TwbcI06t6meQXwGKakmapyBGUt51mv_0FvwhR9Xk9zXi8VE9lSpt7sKRNDShG7BzOM6jltPaet1Tz61WPvD9yfbDNwsgdurcPd_3T0anUpstxv26228g</recordid><startdate>201512</startdate><enddate>201512</enddate><creator>Park, Soojin</creator><creator>Baek, Hyunjung</creator><creator>Jung, Kyung‐Hwa</creator><creator>Lee, Gihyun</creator><creator>Lee, Hyeonhoon</creator><creator>Kang, Geun‐Hyung</creator><creator>Lee, Gyeseok</creator><creator>Bae, Hyunsu</creator><general>John Wiley &amp; Sons, Inc</general><general>John Wiley and Sons Inc</general><scope>24P</scope><scope>WIN</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>201512</creationdate><title>Bee venom phospholipase A2 suppresses allergic airway inflammation in an ovalbumin‐induced asthma model through the induction of regulatory T cells</title><author>Park, Soojin ; Baek, Hyunjung ; Jung, Kyung‐Hwa ; Lee, Gihyun ; Lee, Hyeonhoon ; Kang, Geun‐Hyung ; Lee, Gyeseok ; Bae, Hyunsu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4616-1c8ebf3122156fb68236a3bdc0ed0cb23ac1a6fd247a112b5381057ee20c96513</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Allergies</topic><topic>Arthritis</topic><topic>Asthma</topic><topic>Binding sites</topic><topic>bvPLA2</topic><topic>Cytokines</topic><topic>Gene expression</topic><topic>Immunoglobulins</topic><topic>Inflammation</topic><topic>Lymphocytes</topic><topic>mannose receptor (CD206)</topic><topic>Original Research</topic><topic>regulatory T cells</topic><topic>Signal transduction</topic><topic>Tuberculosis</topic><topic>Venom</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Park, Soojin</creatorcontrib><creatorcontrib>Baek, Hyunjung</creatorcontrib><creatorcontrib>Jung, Kyung‐Hwa</creatorcontrib><creatorcontrib>Lee, Gihyun</creatorcontrib><creatorcontrib>Lee, Hyeonhoon</creatorcontrib><creatorcontrib>Kang, Geun‐Hyung</creatorcontrib><creatorcontrib>Lee, Gyeseok</creatorcontrib><creatorcontrib>Bae, Hyunsu</creatorcontrib><collection>Wiley-Blackwell Open Access Titles</collection><collection>Wiley Free Content</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Immunity, Inflammation and Disease</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Park, Soojin</au><au>Baek, Hyunjung</au><au>Jung, Kyung‐Hwa</au><au>Lee, Gihyun</au><au>Lee, Hyeonhoon</au><au>Kang, Geun‐Hyung</au><au>Lee, Gyeseok</au><au>Bae, Hyunsu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Bee venom phospholipase A2 suppresses allergic airway inflammation in an ovalbumin‐induced asthma model through the induction of regulatory T cells</atitle><jtitle>Immunity, Inflammation and Disease</jtitle><addtitle>Immun Inflamm Dis</addtitle><date>2015-12</date><risdate>2015</risdate><volume>3</volume><issue>4</issue><spage>386</spage><epage>397</epage><pages>386-397</pages><issn>2050-4527</issn><eissn>2050-4527</eissn><abstract>Bee venom (BV) is one of the alternative medicines that have been widely used in the treatment of chronic inflammatory diseases. We previously demonstrated that BV induces immune tolerance by increasing the population of regulatory T cells (Tregs) in immune disorders. However, the major component and how it regulates the immune response have not been elucidated. We investigated whether bee venom phospholipase A2 (bvPLA2) exerts protective effects that are mediated via Tregs in OVA‐induced asthma model. bvPLA2 was administered by intraperitoneal injection into control and OVA‐challenged mice. The Treg population, total and differential bronchoalveolar lavage fluid (BALF) cell count, Th2 cytokines, and lung histological features were assessed. Treg depletion was used to determine the involvement of Treg migration and the reduction of asthmatic symptoms. The CD206‐dependence of bvPLA2‐treated suppression of airway inflammation was evaluated in OVA‐challenged CD206‐/‐ mice. The bvPLA2 treatment induced the Tregs and reduced the infiltration of inflammatory cells into the lung in the OVA‐challenged mice. Th2 cytokines in the bronchoalveolar lavage fluid (BALF) were reduced in bvPLA2‐treated mice. Although bvPLA2 suppressed the number of inflammatory cells after OVA challenge, these effects were not observed in Treg‐depleted mice. In addition, we investigated the involvement of CD206 in bvPLA2‐mediated immune tolerance in OVA‐induced asthma model. We observed a significant reduction in the levels of Th2 cytokines and inflammatory cells in the BALF of bvPLA2‐treated OVA‐induced mice but not in bvPLA2‐treated OVA‐induced CD206‐/‐ mice. These results demonstrated that bvPLA2 can mitigate airway inflammation by the induction of Tregs in an OVA‐induced asthma model. bvPLA2, as a modulator of Treg population, suppresses allergic inflammation in OVA‐induced asthma model. bvPLA2‐induced Treg recruitment to the lungs is correlated with CD206 to ameliorate allergic inflammation.</abstract><cop>England</cop><pub>John Wiley &amp; Sons, Inc</pub><pmid>26734460</pmid><doi>10.1002/iid3.76</doi><tpages>12</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2050-4527
ispartof Immunity, Inflammation and Disease, 2015-12, Vol.3 (4), p.386-397
issn 2050-4527
2050-4527
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4693726
source DOAJ Directory of Open Access Journals; Wiley Online Library Journals Frontfile Complete; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Wiley-Blackwell Open Access Titles; PubMed Central
subjects Allergies
Arthritis
Asthma
Binding sites
bvPLA2
Cytokines
Gene expression
Immunoglobulins
Inflammation
Lymphocytes
mannose receptor (CD206)
Original Research
regulatory T cells
Signal transduction
Tuberculosis
Venom
title Bee venom phospholipase A2 suppresses allergic airway inflammation in an ovalbumin‐induced asthma model through the induction of regulatory T cells
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T10%3A34%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Bee%20venom%20phospholipase%20A2%20suppresses%20allergic%20airway%20inflammation%20in%20an%20ovalbumin%E2%80%90induced%20asthma%20model%20through%20the%20induction%20of%20regulatory%20T%20cells&rft.jtitle=Immunity,%20Inflammation%20and%20Disease&rft.au=Park,%20Soojin&rft.date=2015-12&rft.volume=3&rft.issue=4&rft.spage=386&rft.epage=397&rft.pages=386-397&rft.issn=2050-4527&rft.eissn=2050-4527&rft_id=info:doi/10.1002/iid3.76&rft_dat=%3Cproquest_pubme%3E1754524861%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2289713965&rft_id=info:pmid/26734460&rfr_iscdi=true